
Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-5.89%
-1.12%
-2.01%
-0.33%
-0.18%
Most Trending
-5.89%
-1.12%
-2.01%
-0.33%
-0.18%
16 Jan 2026$MU Micron is set to lead the S&P 500 at the open, climbing 5.7% in pre-market action as Wall Street futures rise up to 0.5%. The boost comes amid easing geopolitical tensions, but the main driver is insider buying: board member Mark Liu purchased $7.8 million in shares, signaling confidence in the stock despite its 218% gain over the past year. Strong demand for flash memory chips from AI, data centers, and cloud infrastructure is supporting optimism ahead of the session.
$SNDK SanDisk is also moving higher in pre-market trading, up 5%, with investors positioning for continued strength in memory and storage. The sector-wide momentum is creating opportunities for traders looking at tech leadership.
$SSNLF Samsung rises 5.6% in pre-market trading after analysts raised price targets. Rising chip prices are boosting projected profits, and traders are watching to see if this momentum carries into the session.
$WDC Western Digital adds 3.1% pre-market as it prepares to implement a strategic business split, drawing investor interest ahead of the open.
$STX Seagate is up 3% before the market opens, benefiting from the broad rally in storage and memory chips. Traders are tracking demand trends closely for potential early gains.
$JBHT JB Hunt is down 5% in pre-market despite reporting solid quarterly results. A 2% year-over-year sales decline combined with a recent 50% run has pushed valuations higher, prompting the market to take early profits before the open.
$ASTS AST SpaceMobile gained 6.3% yesterday and is up another 5% pre-market after being selected for the U.S. missile defense SHIELD program. Strategic news like this is driving pre-market excitement in aerospace stocks.
$IBRX ImmunityBio is surging 20% in pre-market trading following yesterday’s 31% gain. Projected revenues from its bladder cancer drug Anktiva are now $113 million, up 700% from earlier guidance, making it a focus for biotech traders at the open.
Pre-market action shows chips leading the way, but volatility in logistics, biotech, and aerospace suggests traders should prepare for sharp moves once the market opens. Insider buys, analyst upgrades, and strategic wins are all setting the stage for an active session.
Join StocksRunner.com for daily market updates, expert analyses, and actionable insights.
Signup now for FREE and stay ahead of the market curve!
Find out what 10,000+ subscribers already know.
Real-time insights for informed decisions.
Limited slots available, SignUp Now!
Please note that the content above should not be considered as investment advice or marketing. It does not take into account the personal data and requirements of any individual. This content is not a substitute for the reader's own judgment and should not be considered as advice or a recommendation for buying or selling any securities or financial products.
Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Real-time stock market updates
Expert stock analysis
Investment strategies
Top stock recommendations
Trading signals and opportunities
Discover what is happening right now and piece together the key data activity before the major news outlets catch on. Stay ahead of the trends
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.